Compare AbbVie Inc (ABBV) vs Dicks Sporting Goods Inc (DKS) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Dick's Sporting Goods (DKS) trades at $229.02, down 3.03% on the day, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with consistent earnings beats, a P/E of 22.3, and a net income margin of 4.71%. Recent developments include the launch of ScoreCard+ loyalty program and partnerships with Lids, enhancing growth prospects amid positive analyst sentiment.

The outlook for DKS is positive, supported by robust earnings performance and strategic initiatives. Risks include potential fiduciary concerns highlighted in recent legal investigations and competitive pressures. With a consensus price target of $261, representing a 14% upside, the stock presents a compelling opportunity, though investors should monitor execution risks and market volatility.